Angiogenesis in urological malignancy: prognostic indicator and therapeutic target
- 1 April 1999
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 83 (5) , 535-556
- https://doi.org/10.1046/j.1464-410x.1999.00018.x
Abstract
No abstract availableThis publication has 185 references indexed in Scilit:
- An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinomaEuropean Journal Of Cancer, 1997
- EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factorsEuropean Journal Of Cancer, 1997
- Intratumoral vascularity as a prognostic factor in cancers of the urogenital tractEuropean Journal Of Cancer, 1996
- Role of integrins in angiogenesisEuropean Journal Of Cancer, 1996
- Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endotheliumNature, 1995
- Failure of blood-island formation and vasculogenesis in Flk-1-deficient miceNature, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.Proceedings of the National Academy of Sciences, 1993
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990